Does Regeneron Still Offer Value After Strong Five Year Share Price Gains?
-
If you are wondering whether Regeneron Pharmaceuticals at around $779 a share is still worth buying, you are not alone. This article is all about what that price actually implies about value.
-
The stock has climbed 3.6% over the last week and 3.1% in the past month, adding to a solid 9.0% year to date and 62.3% gain over five years, which suggests the market already sees meaningful long term potential.
-
Recent attention has centered on Regeneron’s broad immunology and ophthalmology franchises, plus ongoing progress across its R and D pipeline. This keeps reinforcing the narrative that this is not a one drug story. At the same time, partnerships with larger pharma players and continued investment in next generation antibody…
